Baxter’s REVACLEAR Dialyzer May Offer New Benefits
A new study of 37,500 HD patient records found that use of a REVACLEAR high flux dialyzer was linked to the need for 100 to 600 fewer units of ESA per treatment than matched patients who used an Optiflux® 160 or 180 dialyzer. Researchers also noted a trend toward lower IV iron doses with the Revaclear—while keeping the same HD dose and hemoglobin level.
Read the full article » | Posted 08-09-2016
Related Articles
- Death of Cannulation Expert, Educator and Home Dialysis Champion, Stuart Mott Posted 07-12-2024
- PD and Home HD Sessions and Posters from the 2024 NKF Spring Clinicals Posted 06-14-2024
- New, Validated Survey of Home Dialysis Patients’ Experience of Care Posted 06-14-2024
- Baxter Launches MyPD Digital Management App in Korea Posted 06-14-2024